Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG. Zheng B, et al. Among authors: yu sf. Mol Cancer Ther. 2009 Oct;8(10):2937-46. doi: 10.1158/1535-7163.MCT-09-0369. Epub 2009 Oct 6. Mol Cancer Ther. 2009. PMID: 19808977
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D. Burington B, et al. Among authors: yu n, yu sf. Sci Transl Med. 2011 Mar 16;3(74):74ra22. doi: 10.1126/scitranslmed.3001620. Sci Transl Med. 2011. PMID: 21411738
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG. Li D, et al. Among authors: yu sf. Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18. Mol Cancer Ther. 2013. PMID: 23598530
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.
Williams SP, Ogasawara A, Tinianow JN, Flores JE, Kan D, Lau J, Go M, Vanderbilt AN, Gill HS, Miao L, Goldsmith J, Rubinfeld B, Mao W, Firestein R, Yu SF, Marik J, Terwisscha van Scheltinga AG. Williams SP, et al. Among authors: yu sf. Oncotarget. 2016 May 3;7(18):25103-12. doi: 10.18632/oncotarget.8390. Oncotarget. 2016. PMID: 27029064 Free PMC article.
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR. Pillow TH, et al. Among authors: yu sf. Mol Cancer Ther. 2017 May;16(5):871-878. doi: 10.1158/1535-7163.MCT-16-0641. Epub 2017 Feb 21. Mol Cancer Ther. 2017. PMID: 28223423
495 results